drugset / Trial / NCT02938624
Anti PD-1 Neo-adjuvant Treatment for NSCLC
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A single arm, phase I, dose escalation trial and expansion cohort, examining the safety and feasibility of neoadjuvant pembrolizumab treatment for early resectable NSCLC patients. Hypothesis: The investigators hypothesize that response rate to neo-adjuvant pembrolizumab will be higher than the response rate of advanced NSCLC patients.
Timeline
- Start
- 2017-01-07
- Primary completion
- 2021-08
- Completion
- 2021-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 100 mg | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |